Aspen Neuroscience Reports Breakthrough 12-Month Results in Personalised Stem Cell Trial

The Personalised Repair of the Parkinson’s Brain Twelve-month data from the ASPIRO clinical trial has confirmed that a new approach to cell therapy is achieving significant, measurable improvements in daily life for people with the condition. The results, presented at the AD/PD™ 2026 conference in Copenhagen, focus on a treatment called Sasineprocel. Unlike previous attempts at stem cell therapy that used generic donor cells, this method is entirely personalised, using a person’s own skin cells to create new dopamine-producing neurons. Because the treatment uses the patient's own biological material, it bypasses the need for lifelong immunosuppressant drugs. This is a major clinical hurdle cleared, as it avoids the harsh side effects usually associated with preventing the body from rejecting foreign "donor" cells. The trial focused on safety and dose levels, but the functional results have been the standout feature of the one-year report. Participants in the trial saw their "Good ON" time—the periods during the day when symptoms are well-controlled without troublesome involuntary movements—increase by an average of over two hours. This was paired with a significant drop in motor symptom scores. On the MDS-UPDRS Part III scale, which clinicians use to measure physical progression, patients improved by an average of 13.5 to 15.5 points. Perhaps most importantly, the reported quality of life for those in the low-dose group improved by over 50%. Brain imaging has confirmed that these transplanted cells are not just surviving, but are actively integrating into the putamen, the area of the brain most starved of dopamine. By physically replacing the lost neurons, the therapy aims to rebuild the neural circuitry rather than just temporarily masking the symptoms with medication. In fact, some participants were able to reduce their daily intake of Levodopa while still maintaining these improved physical gains. The safety profile remains strong, with no serious surgical complications or cases of severe graft-induced dyskinesia reported. Based on these stable, one-year results, Aspen Neuroscience is now moving toward a much larger Phase 3 study. This marks a shift in the landscape of care, moving away from the passive management of decline and toward a regenerative model where the body’s own cells are used to repair the damage.